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studies conﬁrmed an EMP. The adjuvant treatment was external radiotherapy, 36Gy in 18 sessions. (3) We have reviewed Pubmed
articles found using the terms “extramedullary plasmacytoma” and “radiotherapy”, selecting those related to nasal location and
limiting them to the last 10 years.
Results. (1) Both patients are free of disease one year after the end of the radiotherapy; (2) the articles reviewed showed rates of
local control from 80 to 100% with radiotherapy.
Conclusion. Due to its high radiosensibility, radiotherapy is considered the treatment of choice in EMP.
http://dx.doi.org/10.1016/j.rpor.2013.03.263
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Introduction. Malignant paragangliomas (PGs) represent rare tumors of neuroendocrine origin. Only a small percentage of patients
ultimately develop metastatic disease. Rates of malignancy are believed to be 2–4% for jugular-tympanic tumors, 6% for carotid
body tumors, and 16–19% for vagal tumors.
Objectives. We present a case of a paraganglioma of the carotid body and we discuss and review the literature.
Method. A male of 68 years old presented to the emergency department for evaluation of intense chronic back pain and gradual
onset of lower extremity weakness over one month. No history of bladder and bowel incontinence was reported. Aside from mild
paresthesia in lower extremities, sensation in his upper extremities was intact. Radiographic studies on admission included
a normal chest radiograph and a normal blood test. Magnetic resonance imaging (MRI) with gadolinium of his lumbar spine
showed abnormal bone marrow signal enhancement with bony destruction at the level of L3 and L5. CT scans of his neck, thorax
and abdomen identify a left cervical mass of 6 cm in maximum diameter. On examination, a pathological specimen obtained
through CT-guided biopsy revealed the presence of a paraganglioma. Then the patient was treated with radiation therapy to a
total dose of 30Gy in once-daily 3Gy fraction over affected vertebra followed by the irradiation of the left lateral neck and the
supraclavicular area to a total dose of 60Gy in 2Gy daily fractions.
Results. Ten months after ﬁnishing the treatment, the patient is free of back pain and a complete response of the left cervical
mass was achieved.
Conclusions. Clinical beneﬁt was derived from aggressive treatment. However, careful consideration of the risks of observation
versus intensive therapy should be undertaken when managing these patients.
http://dx.doi.org/10.1016/j.rpor.2013.03.264
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Introduction. Head and neck cancer is a disease with an incidence of approximately 5–10% of tumor pathology. In elderly patients
sometimes the treatment is different than young patients. We conducted a systematic review of head and neck cancer patients
diagnosed in our department between January 2010 and December 2011. The aim is to describe the characteristics of our
population and the treatment given.
Patients and methods. A retrospective review of patients newly diagnosed with head and neck cancer and who received active
treatment for cancer, between January 2010 and December 2011. We found 18 new cases in that period with the following
characteristics: 16 men and 2 women. The mean age was 76.45 years with an age range between 71 and 81 years.
Results. Tumor stage: IIA in 7 patients (38.9%), III in 5 patients (27.8%) and VAT in 6 patients (33.3%). Tumor site: oral cavity in 9
patients (50%), pharynx in 7 patients (38.9%), and larynx: 2 patients (11.1%). 10 patients underwent radical surgery, subsequently
receiving adjuvant therapy. 8 patients received chemoradiotherapy as a radical treatment. Postoperative treatment was concur-
rent radiotherapy with cisplatin in 3 patients and radiotherapy with concomitant cetuximab in the other 7 patients. For the 8
patients not undergoing surgery, treatment scheme was radiotherapy with concomitant cisplatin in four patients, and concomi-
tant radiotherapy with cetuximab in the other four. All patients completed treatment without severe complications and good
tolerance.
Conclusions. The demographics of our population means that we ﬁnd large number of patients over 70 years. The therapeutic
approach should not be conditional on their age, being in most patients identical attitude subsidiary than younger patients.
There is an increase of cetuximab use in combination with radiation therapy in place of cisplatin, because of lower toxicity and
good results. We need a long-term monitoring to met survival results.
http://dx.doi.org/10.1016/j.rpor.2013.03.265
